Key Highlights
Thirty-six million people die each year from non-communicable diseases like heart disease and stroke, diabetes, cancer and chronic lung disease.
Source: http://www.who.int/nmh/events/un_ncd_summit2011/ncd_video/en/index.html.
In particular, cancer is the leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008.
Source: http://www.who.int/mediacentre/factsheets/fs29 7/en/.
Global demand for effective, safe and easy to administer cancer treatments for these types of diseases is increasing rapidly.
Our Goal
Our immediate goal is to receive worldwide regulatory approval in several therapeutic indications for our lead product, targeting tumor types where there is an established medical need and where little or few treatment options exist.
Key Highlights
- Progressing development:
The progressing development of a once-daily proteolytic proenzyme cancer treatment through non-clinical and clinical development, and ultimately, obtaining regulatory approval as an effective, clinically proven therapeutic option; - Multiple mechanisms of action:
Unlike many products approved for the treatment of cancer, our treatment exerts multiple effects on cancerous cells which inhibits tumor growth and potentially stops it from spreading throughout the body; - Encouraging data from patient treatment:
Scientific research undertaken over the last 15 years and the clinical experience from treating patients in the UK and Australia has provided evidence that PRP may be an effective treatment against cancer, and warrants further development; - Unique intellectual property:
We are focusing on building a significant portfolio of intellectual property around our scientific understanding of the effects of proteolytic proenzyme in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.